4 completed, 1 recruiting, 1 unknown. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Cancer of Unknown Primary Site: new trials by email Literature Review of Cancer of Unknown Primary Site trials Research Report on Cancer of Unknown Primary Site
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) F520 combined with chemotherapy, placebo combined with chemotherapy - Cancer of Unknown Primary Site | Phase 2 / Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 402 | 2026-07-08 | 2026-08-12 |
| Sintilimab in Cancer of Unknown Primary Sintilimab - Cancer of Unknown Primary Site | Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2021-08-26 | 2026-02-25 |
| Nivolumab/Ipilimumab in Second Line CUP-syndrome Nivolumab/Ipilimumab - Cancer of Unknown Primary Site | Phase 2 | Unknown | University Hospital Heidelberg | 194 | 2019-12-12 | 2020-04-15 |
| Trial of Pembrolizumab in Cancer of Unknown Primary Pembrolizumab - Cancer of Unknown Primary Site | Phase 2 | Completed | Imperial College London | 35 | 2019-02-22 | 2026-05-04 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Teysuno, Capecitabine - Gastrointestinal Cancer, Cancer of Unknown Primary Site | Phase 2 | Completed | University of Edinburgh | 59 | 2014-02-05 | 2023-05-12 |
Neoplasms, Unknown Primary (6) · Bile Duct Neoplasms (1) · Carcinoma (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Neoplasm Metastasis (6) · Neoplastic Processes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Neoplasms (5) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Gastrointestinal Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1)
Bevacizumab (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Drug Therapy (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · HhAntag691 (1) · Ipilimumab (1) · Nivolumab (1) · Paclitaxel (1) · Vemurafenib (1) · alectinib (1) · atezolizumab (1) · cobimetinib (1)
Hoffmann-La Roche (1) · Imperial College London (1) · M.D. Anderson Cancer Center (1) · Shandong New Time Pharmaceutical Co., LTD (1) · University Hospital Heidelberg (1) · University of Edinburgh (1)
United Kingdom (3) · Germany (2) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Colombia (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · Finland (1) · France (1)
Harpreet Wasan, MBBS, FRCP (1) · Kanwal Raghav (1) · Sally Clive, MBChB (1) · Sarah Ngan, MBBS, FRCP (1) · Sheela Rao, MBBS, FRCP (1)
PMID 37875494, PMID 39096924, PMID 42691436
2017 (1)